Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles

被引：0

作者：

Goepfert, P. ^{[1
]}

Elizaga, M. ^{[2
]}

Montefiori, D. ^{[3
]}

Hural, J. ^{[2
]}

DeRosa, S. ^{[2
]}

Tomaras, G. ^{[3
]}

Seaton, K. ^{[3
]}

Sato, A. ^{[2
]}

Ouedraogo, L. ^{[4
]}

Donastorg, Y. ^{[5
]}

Cardinali, M. ^{[4
]}

Lama, J. ^{[6
]}

Baden, L. ^{[7
]}

Keefer, M. ^{[8
]}

McElrath, J. ^{[2
]}

Kalams, S. ^{[9
]}

Robinson, H. ^{[10
]}

机构：

[1] Univ Alabama Birmingham, Birmingham, AL USA

[2] Fred Hutchinson Canc Res Inst, Seattle, WA 98104 USA

[3] Duke Univ, Durham, NC USA

[4] NIAID, Vaccine Clin Res Branch, Bethesda, MD 20892 USA

[5] Unidad Vacunas IDCP COIN DIGECITSS, Santo Dominago, Dominican Rep

[6] Asociac Civil IMPACTA Salud & Educ, Lima, Peru

[7] Brigham & Womens Hosp, Boston, MA 02115 USA

[8] Univ Rochester, Rochester, NY USA

[9] Vanderbilt Univ, Nashville, TN USA

[10] GeoVax Inc, Smyma, CA USA

来源：

RETROVIROLOGY | 2012年 / 9卷

关键词：

Vaccinia; Modify Vaccinia Ankara Virus; Avidity Index; Antibody Avidity; Immunogenicity Testing;

D O I：

10.1186/1742-4690-9-S2-O56

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

引用

页数：1

共 50 条

[41] HIGHLY IMMUNOGENIC HUMAN IMMUNODEFICIENCY VIRUS-LIKE PARTICLES ARE PRODUCED BY RECOMBINANT VACCINIA VIRUS-INFECTED CELLS
VZOROV, AN
BUKRINSKY, MI
GRIGORIEV, VB
TENTSOV, YY
BUKRINSKAYA, AG
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (01) : 29 - 36
[42] Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction
Behboudi, S
Moore, A
Gilbert, SC
Nicoll, CL
Hill, AVS
VACCINE, 2004, 22 (31-32) : 4326 - 4331
[43] Immunogenicity of virus-like particles containing modified goose parvovirus VP2 protein
Chen, Zongyan
Li, Chuanfeng
Zhu, Yingqi
Wang, Binbin
Meng, Chunchun
Liu, Guangqing
VIRUS RESEARCH, 2012, 169 (01) : 306 - 309
[44] Adeno-Associated Virus-Like Particles as New Carriers for B-Cell Vaccines: Testing Immunogenicity and Safety in BALB/c Mice
Manzano-Szalai, Krisztina
Thell, Kathrin
Willensdorfer, Anna
Weghofer, Margit
Pfanzagl, Beatrix
Singer, Josef
Ritter, Mirko
Stremnitzer, Caroline
Flaschberger, Ingo
Michaelis, Uwe
Jensen-Jarolim, Erika
VIRAL IMMUNOLOGY, 2014, 27 (09) : 438 - 448
[45] Immunogenicity and Antigenicity of Rabbit Hepatitis E Virus-Like Particles Produced by Recombinant Baculoviruses
Bai, Huimin
Kataoka, Michiyo
Ami, Yasushi
Suzaki, Yuriko
Takeda, Naokazu
Muramatsu, Masamichi
Li, Tian-Cheng
VIRUSES-BASEL, 2021, 13 (08):
[46] Cell-Mediated Immunity Induced by two Recombinant Modified Vaccinia Virus Ankara Vaccines Delivering the G Antigen of Nipah Virus
Kalodimou, G.
Veit, S.
Jany, S.
Luelf-Averhoff, A. T.
Sutter, G.
Volz, A.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 129 - 129
[47] IMMUNOGENICITY AND SAFETY OF A RECOMBINANT VACCINIA VIRUS-VACCINE EXPRESSING THE CARCINOEMBRYONIC ANTIGEN GENE IN A NONHUMAN PRIMATE
KANTOR, J
IRVINE, K
ABRAMS, S
SNOY, P
OLSEN, R
GREINER, J
KAUFMAN, H
EGGENSPERGER, D
SCHLOM, J
CANCER RESEARCH, 1992, 52 (24) : 6917 - 6925
[48] Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus
Di Mario, Giuseppina
Soprana, Elisa
Gubinelli, Francesco
Panigada, Maddalena
Facchini, Marzia
Fabiani, Concetta
Garulli, Bruno
Basileo, Michela
Cassone, Antonio
Siccardi, Antonio
Donatelli, Isabella
Castrucci, Maria R.
PATHOGENS AND GLOBAL HEALTH, 2017, 111 (02) : 69 - 75
[49] A Novel Recombinant Modified Vaccinia Ankara Virus expressing Interleukin-13 Receptor α2 Antigen for Potential Cancer Immunotherapy
Sato, Yuki
Vatsan, Ramjay
Joshi, Bharat H.
Husain, Syed R.
Puri, Raj K.
CURRENT MOLECULAR MEDICINE, 2024, 24 (06) : 758 - 770
[50] Immunogenicity of DNA and Recombinant Sendai Virus Vaccines Expressing the HIV-1 gag Gene
Tsugumine Shu
Tetsuro Matano
Mamoru Hasegawa
Virologica Sinica, 2008, (04) : 295 - 304

← 1 2 3 4 5 →